Puma Biotechnology (PBYI) Common Equity (2010 - 2026)

Puma Biotechnology has reported Common Equity for 17 years, with the latest figure at $128.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 32.24% year-over-year to $128.4 million; the trailing twelve-month figure through Mar 2026 stood at $128.4 million (up 32.24% YoY), and the FY2025 full-year result was $130.3 million, up 41.48% from the prior year.
• Common Equity for Q1 2026 stood at $128.4 million, down from $130.3 million in the prior quarter.
• The five-year high for Common Equity was $130.3 million in Q4 2025, with the low at $7.1 million in Q1 2022.
• Historically, Common Equity has averaged $62.2 million across 5 years, with a median of $51.0 million in 2024.
• The largest YoY upside for Common Equity was 983.4% in 2022 against a maximum downside of 56.26% in 2022.
• Puma Biotechnology's Common Equity stood at $21.6 million in 2022, then soared by 147.33% to $53.4 million in 2023, then soared by 72.38% to $92.1 million in 2024, then soared by 41.48% to $130.3 million in 2025, then dropped by 1.48% to $128.4 million in 2026.
• The last three Common Equity figures came in at $128.4 million (Q1 2026), $130.3 million (Q4 2025), and $115.3 million (Q3 2025), per Business Quant data.